All In Biotech

Free tool

FAERS Monitor: Revcovi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761092 or its brand name (Revcovi, Elapegademase-Lvlr). Reports on generic versions are filed under their own applications.

Reports

299

Serious

80

27% of reports

Hospitalization

47

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nasopharyngitis37
  • cough23
  • covid-1922
  • bone marrow transplant13
  • pneumonia13
  • sinusitis13
  • weight decreased12
  • pyrexia11
  • injection site pain10
  • off label use10
  • rhinorrhoea10
  • diarrhoea8
  • product dose omission8
  • rash8
  • weight increased8

Reports by year received

View as table
YearReports
201932
202031
202120
202251
202364
202457
202536
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,860 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bone marrow transplantSignal13485.6284.85,772
nasopharyngitisSignal3714.110.4442
rhinorrhoeaSignal1010.95.980
sinusitisSignal138.95.284
covid-19Signal228.85.9146
product dose omissionSignal88.64.447
coughSignal235.83.987
weight decreasedSignal123.01.714
pneumoniaSignal132.81.714
weight increasedSignal82.51.36
injection site painSignal102.31.26
pyrexiaSignal112.21.36
rash81.30.70
diarrhoea80.90.40
off label use100.80.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.